Abstract: Methods for manufacturing a magnetic stripe on a card element of a card-like data carrier. involve applying at least a portion of a magnetic stripe material layer onto a card element surface of the card element using different techniques. The application of the portion of the magnetic stripe material layer onto the card element surface generates a magnetic stripe on the card element surface such that the magnetic stripe has a stripe length that is less than a length of the card element surface and has a stripe width that is less than a width of the card element surface.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Method and apparatus for transforming organic and inorganic solid urban waste into aggregates, comprising an extruding machine connected to a reactor. The extruding machine is formed by an extrusion cylinder through which a piston circulates inside an extrusion cavity, which comprises three sections and is fed with a parget obtained after pre-processing the waste. The end of the third section is connected to the reactor through an opening. The reactors longitudinal shaft is formed by a rotatory steel shaft in which some steel blades are arranged, whose ends play the roles of cutting, hammering, punching and hydraulic helix as they rotate. Between the end of the blades and the wall of the reactor, there is a clearance of more than 0.1 mm of thickness. The reactor has a discharge valve to discharge the parget present in the boundary area through some openings, once it has been processed by a series of pressure, vibration energy and decompression cycles.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Method and apparatus for transforming organic and inorganic solid urban waste into aggregates, comprising an extruding machine connected to a reactor. The extruding machine is formed by an extrusion cylinder through which a piston circulates inside an extrusion cavity, which comprises three sections and is fed with a parget obtained after pre-processing the waste. The end of the third section is connected to the reactor through an opening. The reactors longitudinal shaft is formed by a rotatory steel shaft in which some steel blades are arranged, whose ends play the roles of cutting, hammering, punching and hydraulic helix as they rotate. Between the end of the blades and the wall of the reactor, there is a clearance of more than 0.1 mm of thickness. The reactor has a discharge valve to discharge the parget present in the boundary area through some openings, once it has been processed by a series of pressure, vibration energy and decompression cycles.

Abstract: Method and apparatus (100) for transforming organic and inorganic solid urban waste into aggregates, comprising an extruding machine connected to a reactor. The extruding machine is formed by an extrusion cylinder (103) through which a piston circulates (104) inside an extrusion cavity (106), which comprises three sections (107, 110, 111) and is fed with a parget obtained after pre-processing the waste. The end (115) of the third section (111) is connected to the reactor (112) through an opening (114). The reactor's longitudinal shaft is formed by a rotatory steel shaft (116) in which some steel blades are arranged (108), whose ends play the roles of cutting, hammering, punching and hydraulic helix as they rotate. Between the end of the blades and the wall of the reactor, there is a clearance of more than 0.1 mm of thickness.

Abstract: It is provided a lithium metal anode coated with a protective monolayer disposed on at least a portion of the lithium metal anode, the protective monolayer consisting of a polymer; at least one inorganic particle selected from the group consisting of Al2O3, MnO, MnO2, SiO2, TiO2, ZnO, ZrO2, Fe2O3, CuO, a silicate, an aluminosilicate, a borosilicate, and an oxysalt, or any one of the mentioned inorganic particles which are functionalized; wherein the protective monolayer has a thickness from 0.01 to 10 ?m, the inorganic particles have an average diameter from 1 to 500 nm, and the at least one inorganic particle is in an amount of 0.01 to 30 wt % related to the amount of polymer. It is also provided a method for the preparation of the protected anode, as well as a lithium metal battery comprising it.

Abstract: It is provided a chalcogenide polymer-carbon composite comprising from 70.0 to 99.0 mol % of a chalcogenide; from 0.5 to 20.0 mol % of carbon in the form of a carbonaceous material, and from 0.5 to 10.0 mol % of a crosslinking moiety, with respect to the total amount of chalcogenide, carbon, and crosslinking moiety, wherein the chalcogenide is in the form of chalcogenide chains bonded to the crosslinking moiety and they are forming a structure wherein the carbonaceous material is embedded. It is also provided a process for its preparation, as well as a cathode comprising the chalcogenide polymer-carbon composite, and a battery comprising the cathode.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: An integrated circuit including a ferroelectric random access memory (FRAM) for storing firmware, and a method of updating that firmware. The FRAM is constructed to selectively operate as a 2T2C FRAM memory in a normal operating mode, and as a 1T1C FRAM memory in an update mode. Updating of the stored firmware is performed by placing the FRAM in its update (1T1C) mode and writing the updated code into alternate rows of the 1T1C half-cells at each of a plurality of memory locations, while the other 1T1C half-cells in the other alternate rows retain the original data. Following verification of the updated contents, the original data in the other half-cells are overwritten with the verified updated data, and the operating mode is changed back to the normal (2T2C) operating mode.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: An integrated circuit including a ferroelectric random access memory (FRAM) for storing firmware, and a method of updating that firmware. The FRAM is constructed to selectively operate as a 2T2C FRAM memory in a normal operating mode, and as a 1T1C FRAM memory in an update mode. Updating of the stored firmware is performed by placing the FRAM in its update (1T1C) mode and writing the updated code into alternate rows of the 1T1C half-cells at each of a plurality of memory locations, while the other 1T1C half-cells in the other alternate rows retain the original data. Following verification of the updated contents, the original data in the other half-cells are overwritten with the verified updated data, and the operating mode is changed back to the normal (2T2C) operating mode.

Abstract: Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.

Abstract: An integrated circuit including a ferroelectric random access memory (FRAM) for storing firmware, and a method of updating that firmware. The FRAM is constructed to selectively operate as a 2T2C FRAM memory in a normal operating mode, and as a 1T1C FRAM memory in an update mode. Updating of the stored firmware is performed by placing the FRAM in its update (1T1C) mode and writing the updated code into alternate rows of the 1T1C half-cells at each of a plurality of memory locations, while the other 1T1C half-cells in the other alternate rows retain the original data. Following verification of the updated contents, the original data in the other half-cells are overwritten with the verified updated data, and the operating mode is changed back to the normal (2T2C) operating mode.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. Formula (I).

Abstract: Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.